English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04197986 /

QBGJ398-302

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: